Biocytogen 

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/hPD-L1 mice


Basic characteristics

1.png 


Targeting strategy 

image.png


Protein expression analysis

1.png

Fig 1. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hPD-L1 mice were analyzed by flow cytometry. Mouse PD-L1+ T cells were detectable in the WT C57BL/6 mice, while human PD-L1+ T cells were detectable in the homozygous B-hPD-1/hPD-L1 mice.


2.png

Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hPD-L1 mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1/hPD-L1 mice.


 Human PD-L1 (Tecentriq) mAb efficacy evaluation (MC38-hPD-L1 cell line)


image.png

Fig 3. Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=5). The human PD-L1 antibody Tecentriq significantly inhibited tumor growth, confirming that the B-hPD-1/hPD-L1 mouse model is a powerful tool for in vivo PD-L1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Combination therapy of PD-1(Keytruda) Ab and PD-L1 (Tecentriq) Ab

image.png

Fig 4. Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6).  Anti-hPD-1 antibody Keytruda, anti-hPD-L1 antibody Tecentriq and Combination of anti-hPD-1 antibody Keytruda and anti-hPD-L1 antibody Tecentriq all show significant inhibitory effects. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


 

【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud